Nab-paclitaxel vs paclitaxel liposome for advanced breast cancer: real-world efficacy and safety analysis

Nab-paclitaxel or paclitaxel liposomes remain significantly effective in patients with advanced breast cancer who have failed first or multiline therapy. Nab-paclitaxel is superior to paclitaxel liposome in efficacy evaluation, paclitaxel liposome is superior to nab-paclitaxel in survival outcome.